GMP Lapses At Biocon’s Indian Site – Jitters for Neulasta Biosimilar Plans?
Executive Summary
Biocon’s facility in Bangalore, India, has failed to pass muster with the US FDA, raising questions on whether this could result in a pushback of commercialization timelines for partner Mylan’s biosimilar pegfilgrastim in the US. The European regulator has also not cleared the Bangalore site.
You may also be interested in...
Mylan/Biocon’s Insulin Glargine Has Narrow Window For Approval In US
Thirty-month stay resulting from Sanofi’s patent lawsuit expires on 18 March 2020, two days before Mylan’s application must receive final approval to avoid getting caught in the transition of insulins from drug to biologic regulation. Pre-approval inspection of Biocon’s manufacturing facility resulted in 12 ‘largely procedural’ observations, company says.
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.